SCHEMBL25680207

SCHEMBL25680207

CC(C)(CNC(=O)c1ccc(-c2cncc(-c3cncc(F)c3)n2)cc1)NC(=O)OC(C)(C)C

nearest known ligand 0.39

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
LATS1 O95835 2/20 0.39
AKR1C3 P42330 2/20 0.39
ACACB O00763 3/20 0.37
ACACA Q13085 3/20 0.37
EGLN2 Q96KS0 1/20 0.37
LATS2 Q9NRM7 1/20 0.37
CYP17A1 P05093 1/20 0.37
ULK1 O75385 2/20 0.36
FYN P06241 1/20 0.36
CHEK1 O14757 1/20 0.36
NAMPT P43490 1/20 0.36
KCNH2 Q12809 1/20 0.36
HCRTR1 O43613 1/20 0.35
HCRTR2 O43614 1/20 0.35
DYRK1A Q13627 1/20 0.35
GPR119 Q8TDV5 1/20 0.35
ABL1 P00519 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25209962 0.88 EGLN2 (0.39) AKR1C3EGLN2CYP17A1ULK1FYN
SCHEMBL25680124 0.84 P2RX7 (0.38) AKR1C3ACACBACACACYP17A1FYN
SCHEMBL30438769 0.83 ULK1 (0.40) AKR1C3EGLN2CYP17A1ULK1FYN
SCHEMBL25218243 0.83 ULK1 (0.40) AKR1C3EGLN2CYP17A1ULK1FYN
SCHEMBL29253936 0.83 EGLN2 (0.38) AKR1C3EGLN2CYP17A1ULK1FYN
SCHEMBL25680022 0.83 P2RX7 (0.41) AKR1C3ACACBACACACYP17A1FYN
SCHEMBL29253937 0.80 PDK2 (0.45) CHEK1ABL1
Trifluoroacetic Acid SCHEMBL30439151 0.79 EGLN2 (0.41) AKR1C3EGLN2CYP17A1ULK1CHEK1
SCHEMBL30438905 0.78 HDAC4 (0.57) ACACBACACADYRK1A
SCHEMBL25210972 0.74 CHEK1 (0.50) FYNCHEK1ABL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250122167-A1 Pyrazine Compounds Useful in the Treatment of Parasitic Protozoal Infection GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2025-04-17 US disclosed
EP-4436960-A1 PYRAZINE COMPOUNDS USEFUL IN THE TREATMENT OF PARASITIC PROTOZOAL INFECTION GlaxoSmithKline Intellectual Property Development Limited (GB) 2024-10-02 EP disclosed
CN-118355005-A Pyrazine compounds for the treatment of parasitic protozoal infections 葛兰素史密斯克莱知识产权发展有限公司 2024-07-16 CN disclosed
WO-2023094305-A1 PYRAZINE COMPOUNDS USEFUL IN THE TREATMENT OF PARASITIC PROTOZOAL INFECTION GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2023-06-01 WO disclosed
WO-2023094305-A1 PYRAZINE COMPOUNDS USEFUL IN THE TREATMENT OF PARASITIC PROTOZOAL INFECTION GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2023-06-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250122167-A1 Pyrazine Compounds Useful in the Treatment of Parasitic Protozoal Infection CYP3A5, CYP3A43, CYP51A1 LATS1 1398/4885AKR1C3 1239/4885ACACB 3611/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.